KansasPrescribed does not mean approved

A little clarity before care.

All chapters

Cautions before treatment

Know what to pause and what to ask.

A calm check is more useful than trying to judge a website by its look. Ask about the prescription, the source and the plan for questions once treatment begins.

Start with the short answer
Follow the question.
  1. Before paymentPrescription + source
  2. At deliveryLabel + product questions
  3. During careA clear path to help

Reconsider the care assumption

Look for answers you can check.

Food and Drug Administration (FDA) cautions and federal status as of September 26, 2026.

Offering a prescription drug without a valid prescription breaks federal law.

A claim that a compounded preparation has FDA approval is false.

FDA warns against research-labelled weight-drug products offered for human use; their quality is unknown, and using them may cause harm.

When to seek urgent help

Guidance from MedlinePlus, a government health resource, as of September 17, 2026.

MedlinePlus calls a severe allergic reaction a medical emergency. Possible signs include trouble swallowing, trouble breathing, and swelling in the tongue or face.

For severe signs of an allergic reaction, MedlinePlus directs people to emergency help or the nearest emergency room.

For concerns that are not urgent, ask the person treating you how to report symptoms and get advice. Bring the medicine name and what happened.

Checks before and after delivery

Ask who made and sent the medicine

FDA has found fraudulent labels on compounded semaglutide and tirzepatide that identify nonexistent pharmacies or pharmacies that never made the product.

Ask for the pharmacy identity before paying. Check its board record, then compare it with the label when the parcel arrives.

To meet FDA’s online-pharmacy checklist, a pharmacy needs state licensing, must require a valid prescription and must give you access to a licensed pharmacist.

An unusually low price is a caution to consider with other signs, rather than proof of a problem on its own.

A parcel or instruction that raises questions

FDA handling advice as of September 17, 2026; medicine error reports as of September 26, 2026.

GLP-1 drugs mimic a hormone—a natural chemical messenger in the body—that helps regulate blood sugar and appetite.

FDA advises against using a GLP-1 injection that arrives warm or without enough cooling.

That is not a cold-storage rule for every peptide. Storage depends on the product and its own label.

FDA has received reports of dose errors with compounded semaglutide, some involving hospital care.

If the instructions are unclear, ask the pharmacist or the person who wrote your prescription to explain them before you use the medicine. Keep the label and packaging for that conversation.

Take this with you

Words to start the conversation

  • Can a pharmacist answer questions about this product?
  • What symptoms call for urgent care?
  • Who can clarify the label, storage and instructions?
Chapter notes

Evidence for this chapter

  1. A
    FDA: online pharmacy checks

    For prescription, licensing and pharmacist access.

  2. B
    FDA: weight-drug labels and deliveries

    For research products, fraudulent labels and refrigeration concerns.

  3. C
    FDA: compounded products and approval

    For the limits of product review.

  4. D
    FDA: reports of medicine measurement errors

    For reported problems, without dose instructions.

  5. E
    MedlinePlus: severe allergic reactions

    For urgent signs and emergency help.

  6. F
    Government drug label: tesamorelin (Egrifta SV)

    For the storage instructions on this product’s label.

  7. G
    MedlinePlus: semaglutide storage

    For another product’s storage instructions.